Call 855-808-4530 or email GroupSales@alm.com to receive your discount on a new subscription.
In the field of product liability law, the silo phenomenon — in which different departments of an organization decline to share information with other departments of the same organization or field — is puzzling, since there have been several examples of situations where additional regulation has resulted in additional litigation. For example, in the case of asbestos, a wave of litigation was followed by tightened regulation of asbestos product exposure by the Occupational Safety and Health Administration (OSHA). (The Environmental Protection Agency (EPA) has asbestos regulations as well.) And then there is the enforcement activity of both the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC), (and the FDA’s refusal, to date, to define the term “natural”), all of which have arguably contributed to the current wave of consumer product class actions.
By Steven P. Benenson
In the past several years, plaintiffs’ firms have threatened or brought class actions against different companies under New Jersey’s Truth-in-Consumer Contract Warranty and Notice Act (TCCWNA). Here's what you need to know.
By Mitch Warnock
When you take a catastrophic injury case involving paralysis, it is important to have a thorough understanding of the problems and pitfalls. In this article, the author explores, from personal experience, the different types of future expenses the client can expect to incur.
By Shannon E. McClure and Whitney Mayer
The FDA’s recent approval of 23andMe’s direct-to-consumer genetic test to identify genes associated with 10 common diseases and disorders could result in a widespread expansion of patients armed with individualized health information. This expansion of genetic information in the hands of consumers potentially impacts regulatory and litigation issues for pharmaceutical companies.
Discussion of major rulings out of Texas and California.